Anika Therapeutics (ANIK) Misses Q1 EPS by 62c
Tweet
Share
E-mailGet Alerts ANIK Hot Sheet
Price: $21.13 +1.25%
Revenue Growth %: +5.5%
Financial Fact:
Basic weighted average common shares outstanding: 14.63M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Revenue Growth %: +5.5%
Financial Fact:
Basic weighted average common shares outstanding: 14.63M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
Anika Therapeutics (NASDAQ: ANIK) reported Q1 EPS of ($0.46), $0.62 worse than the analyst estimate of $0.16. Revenue for the quarter came in at $21.26 million versus the consensus estimate of $24.34 million.
For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
- Hawaiian Electric trades at 8.8x P/E, but wildfire risk clouds value case
- Designer Brands (DBI) PT Lowered to $6 at UBS
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
